Publications by authors named "Nikolaos Fytanidis"
Objective: To present the characteristics of patients with potential difficult-to-treat (D2T) PsA.
Methods: We used data from the Greek multicentre registry of PsA patients. D2T PsA was defined as follows: patients with at least 6 months' disease duration, who have failed to at least one conventional synthetic DMARD and at least two biologic DMARDs/targeted synthetic DMARDs with a different mechanism of action and have either at least moderate disease activity (MODA) defined as DAPSA (Disease Activity index in PSoriatic Arthritis) >14, and/or are not at minimal disease activity (MDA).
Article Synopsis
- CPPD arthritis is the second most common crystal-induced arthritis after gout and is typically treated with non-steroidal anti-inflammatory drugs or glucocorticoids.
- There is currently no effective pharmacological treatment to reduce CPPD crystal levels, making it hard to manage in chronic cases, especially for patients with end-stage renal disease.
- A study found that treating two patients with chronic CPPD arthritis and end-stage renal disease with the IL-1β receptor antagonist anakinra led to quick resolution of symptoms and allowed them to stop glucocorticoids, suggesting it may be a safe and effective treatment option.